The three most prominent pharmacological approaches to longevity differ fundamentally in what they target: senolytics clear aged, damaged cells outright; mTOR inhibitors dial back a central growth-signaling pathway; and NAD+ precursors replenish a cofactor that declines with age. A recent review of emerging anti-aging pharmacotherapy classifies these strategies alongside senomorphics and metabolic modifiers like metformin, and finds them at markedly different stages of clinical development. Here is how each works, what compounds represent it, and where the human evidence stands.
Introduction to Pharmacological Longevity Interventions
Modern longevity research is organized around the "hallmarks of aging"—the accumulating molecular and cellular changes thought to drive age-related disease. As the review "Rewinding the Clock" explains, these hallmarks provide a conceptual framework for drug development, with candidate interventions sorted into five broad categories: senolytics, senomorphics, NAD+ precursors, mTOR inhibitors, and metabolic modifiers such as metformin. Each category attacks a different hallmark, which is precisely why they are not interchangeable—and why researchers increasingly see them as potentially complementary rather than competing.
Notably, none of these approaches is yet an approved anti-aging therapy. The clinical trial discussion below reflects publicly reported study activity, not a complete registry, and the mechanisms described reflect current scientific understanding, which may evolve. This article covers drugs and compounds only, not lifestyle interventions.
Senolytics: Targeting Senescent Cells
Senescent cells are cells that have stopped dividing but refuse to die. The problem is not merely their presence but their secretions: the senescence-associated secretory phenotype (SASP), which can be pro-inflammatory or immunosuppressive depending on cell type and timing. Persistent accumulation of these cells is implicated in tissue dysfunction, chronic inflammation, and age-related diseases, even though transient senescence plays beneficial roles in tissue repair and tumor suppression.
Senolytics work by exploiting a weakness: senescent cells upregulate pro-survival and anti-apoptotic pathways—SRC kinases, PI3K-AKT signaling, heat shock proteins, serpines, and BCL-2-related proteins—to survive in a cytotoxic environment they themselves create. Senolytic drugs aim to switch those pro-survival pathways off, selectively inducing apoptosis in the senescent cells. Among the most studied candidates is Navitoclax, a BCL-2 family inhibitor that disrupts BCL-2's interactions with its binding partners. Dasatinib combined with quercetin is another widely cited senolytic pairing.
The clinical picture is early and mixed. Navitoclax has demonstrated proof-of-concept activity but, as Selvita's drug-discovery scientists note, faces limitations in selectivity and safety—it induces apoptosis in non-senescent cells too, and does not act on all senescent cell types. It remains unapproved as a therapeutic, with ongoing trials in indications including thrombocythemia and myelofibrosis rather than aging itself.





